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Abstract
Objective. To assess the efficacy and safety profiles of two different rituximab retreatment regimens in
patients with RA.
Methods. Four hundred and ninety-three RA patients with an inadequate response to MTX recruited into
rituximab Phase II/III studies received further courses of open-label rituximab based on two approaches:
(i) treatment to target (TT): patients assessed 24 weeks after each course and retreated if not in remission
[DAS in 28 joints based on ESR (DAS-28-ESR)52.6]; (ii) treatment as needed (PRN): patients retreated at
the physician’s discretion 524 weeks following the first course and 516 weeks following further courses,
if both swollen and tender joint counts were 58. All courses consisted of i.v. rituximab 2 1000mg
2 weeks apart plus MTX. Observed data were analysed according to treatment strategy.
Results. Multiple courses of rituximab maintained or improved responses irrespective of regimen. TT
provided tighter control of disease activity with significantly greater improvements in DAS-28-ESR and
lower HAQ-disability index scores vs PRN. TT resulted in significantly more patients achieving major
clinical response. PRN resulted in recurrence of disease symptoms between courses, with TT significantly
reducing the incidence of RA flares. Despite more frequent retreatment with TT compared with PRN, the
rates of serious adverse events and serious infections were comparable between regimens.
Conclusions. Retreatment with rituximab based on 24-week evaluations and to a target of DAS-28-ESR
remission leads to improved efficacy and tighter control of disease activity compared with PRN without a
compromised safety profile. TT may be the preferable rituximab treatment regimen for patients with RA.
Key words: Methotrexate-inadequate responder, Treatment to target, Treatment as needed, Retreatment,
Rituximab, Treatment strategy.
Introduction
There is currently increasing interest in the tight control of
RA by using disease activity measures to guide treatment
decisions [1]. Treatment to target (TT) is a treatment strat-
egy tailored to the individual patient, whereby patients are
regularly monitored and treatment is adjusted in order to
achieve a predefined level of disease activity, such as re-
mission, within a certain period of time [26]. Tight control
of disease is desirable for improved control of disease
activity, but may also be associated with better longer
term outcomes such as decreased progression of
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tional capability [1, 4]. Recent guidelines and recommen-
dations for RA treatment advocate this approach [6, 8, 9],
and there is evidence of acceptance of tight disease
control as a concept by the practising rheumatology
community [10].
Rituximab is a therapeutic mAb that selectively targets
CD20
+ B cells. The combination of rituximab with MTX
significantly improves disease symptoms in RA patients
who have had an inadequate response to conventional
DMARD therapy, and has been shown to improve disease
symptoms and protect against joint damage in patients
with an inadequate response to TNF inhibitors [1113].
During the clinical development of rituximab in RA, two
distinct retreatment regimens have been adopted. In initial
studies, second and subsequent courses of rituximab
treatment (hereafter referred to as retreatments) were ad-
ministered based on the presence of a certain number of
active joints and at the discretion of the treating physician.
In more recent Phase III studies, the individual patient’s
disease activity was assessed 24 weeks after each course
of treatment, with further treatment required by protocol
on the basis of this assessment, with the aim of achieving
a target level of disease activity (DAS in 28 joints based on
ESR; DAS-28-ESR <2.6). The 24-week time point for the
assessment of disease activity was based on studies of
the pharmacokinetic and pharmacodynamic profiles of
rituximab, which have shown drug concentrations below
the level of detection and evidence of returning peripheral
B cells for many patients from this time point [12, 14, 15].
The objective of this analysis was to assess the differ-
ences in efficacy and safety of these two different ritux-
imab retreatment regimens—TT and treatment as needed
(PRN)—in patients with RA, with a view to defining an
optimal retreatment regimen. The analysis was based on
pooled data from the rituximab clinical development pro-
gramme in biological-naı ¨ve patients who have had an in-
adequate response to MTX (MTX-IR).
Methods
Patients
Patients retreated with rituximab using the TT regimen
were included from the Study Evaluating Rituximab’s
Efficacy in MTX iNadequate rEsponders (SERENE) [13]
and MIRROR studies [16]. Patients retreated using the
PRN regimen were included from the DANCER study [17]
and the initial rituximab proof of concept study [14], together
with their long-term extensions [18]. Supplementary figure A
(available as supplementary data at Rheumatology Online)
shows the number of patients recruited from each study
along with the retreatment regimen the patients received.
All patients were a minimum of 18 or 21 years of age
(depending on the study) with RA diagnosed according
to the revised 1987 ACR criteria [19]. Disease duration
was at least 6 months. All patients had experienced an
inadequate response to MTX despite current and ongoing
MTX treatment. At study entry, patients had active dis-
ease defined as both a swollen joint count (66 joints)
and a tender joint count (68 joints) 58 at screening and
baseline. In addition, patients had a CRP level of 50.6 or
1.5mg/dl (depending on the study) or an ESR 528mm/h.
Data from patients who were initially randomly assigned to
receive placebo and who were subsequently switched
to receive rituximab were included from the point of first
administration of rituximab 2 1000mg.
All studies were conducted in accordance with the eth-
ical principles of the Declaration of Helsinki and adhered
to the principles outlined in the Guideline for Good Clinical
Practice International Conference on Harmonisation (ICH)
Tripartite Guideline (January 1997). Studies were appro-
ved by the institutional review board or the ethics com-
mittee at each study site. All patients gave written
informed consent. Long-term follow-up of the SERENE
and MIRROR trials were pre-planned extensions of the
original trials and no further ethics approval or informed
consent were required. For the other studies, patients
were transferred into separate long-term extension stu-
dies for which ethics approval and informed consent
were obtained.
Treatment strategies
Patients treated using the TT regimen were assessed
24 weeks after each course of rituximab. Patients
received retreatment if their DAS based on ESR [20] was
52.6. Patients whose DAS-28-ESR was <2.6 were as-
sessed every 8 weeks (or sooner if required) and were
retreated if and when DAS-28-ESR increased to 52.6.
Patients were only permitted a third and subsequent
courses of rituximab if they were considered by the treat-
ing physician to have benefited from either of the initial
two courses.
Patients treated using the PRN regimen were assessed
24 weeks following their initial course of rituximab or pla-
cebo. Only patients achieving a reduction in swollen and
tender joint counts of 520% were permitted retreatment
with rituximab. A second course of rituximab was per-
mitted if both tender and swollen joint counts were 58,
and at the discretion of the treating physician. Patients
were reassessed every 8 weeks for reconsideration of
treatment (although unscheduled visits could occur at
anytime for reassessment if required); however, further
treatment courses were permitted no more frequently than
every 16 weeks following each course, based on these
criteria.
Procedures
All courses of rituximab 2 1000mg were administered
by i.v. infusion on Days 1 and 15 of each treatment course,
with all infusions premedicated with 100mg i.v. methyl-
prednisolone. All patients continued to receive their
pre-baseline dose of MTX (oral or parenteral) at a level
not exceeding 25mg/week. Concomitant glucocorticoids
(410mg/day prednisolone or equivalent) and NSAIDs were
permitted at stable doses. With the exception of rescue
in the SERENE study, i.v. or i.m. glucocorticoids and
additional DMARDs(non-biological orbiological) werepro-
hibited (in the SERENE study, four patients included in this
2224 www.rheumatology.oxfordjournals.org
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non-biological DMARD between Weeks 16 and 23).
Assessments
Assessments of clinical outcomes and physical function
were made at 8-weekly intervals with unscheduled visits
at any time, as required. Clinical outcomes included DAS-
28-ESR and durability of response determined by the
proportion of patients achieving a major clinical re-
sponse (defined as maintenance of ACR70 response for
56 months). Physical function was determined using the
HAQ-disability index (HAQ-DI) [21]. The incidence of flare
(defined as an increase in the patient’s DAS-28-ESR of
>1.2 above their lowest value achieved during that spe-
cific course) within each treatment course was deter-
mined. The time interval between treatment courses for
both regimens was also determined.
Adverse events (AEs) were recorded throughout the
study and graded according to the National Cancer
Institute (NCI) Common Terminology Criteria for Adverse
Events (CTCAEs), version 3. Serious AEs (SAEs) were
defined as events that were fatal, immediately life-
threatening, required hospitalization or prolongation of
an existing period of hospitalization, were medically sig-
nificant or required intervention to prevent one of the
above outcomes. For classification purposes, original ter-
ms were assigned preferred terms using the Medical
Dictionary for Regulatory Activities (MedDRA), version
10.1. Infections were identified using a MedDRA basket
of preferred terms and/or events identified as infections
on the case report form. Serious infection events (SIEs)
were defined as either SAE infections or infections treated
with i.v. antibiotics.
Statistics
In this study, retrospective analyses were performed using
pooled data from biologic-naı ¨ve MTX-IR patients, and
using observed data pooled by treatment strategy, with
no imputation methods applied. Efficacy outcomes (DAS-
28-ESR and HAQ-DI) were included for up to 2 years after
the initial dose of rituximab.
The time to retreatment by course was compared be-
tween retreatment groups using a non-parametric
Wilcoxon test. The pre-course DAS-28-ESR value was
defined as the value obtained before the first infusion of
each rituximab course or the last known value before the
baseline value if the former was missing. The mean
pre-course DAS-28-ESR baseline values were compared
between the TT and PRN groups using a t-test. The pro-
portions of patients experiencing a disease flare by course
and of those achieving a major clinical response were
analysed using Pearson’s chi-square test.
To examine the differences in change in DAS-28-ESR
and HAQ-DI over time between the retreatment regimen
groups, analysis was performed using a repeated meas-
ures random effects model (using all data for a patient at
all time points and including the patient as a random
term). In order to adjust for potential baseline character-
istic differences between the TT and PRN regimen groups,
a propensity score model predicting the probability of
being in the TT or PRN retreatment groups was generated
using multivariable logistic regression. These propensity
scores were then included in the repeated measures
model as a covariate. Variables that were included in the
propensity score adjustment were baseline characteristics
(Table 1), in addition to race (white, black and other), base-
line height, baseline weight, patient global assessment,
patient-assessed pain, physician global assessment and
DAS-28 based on CRP. Safety data were not limited and
were based on all available data from all patients. Overall
rates of AEs and infections per 100 patient-years were
calculated.
Results
Overall, a total of 257 patients were included in the PRN
group and 236 patients were included in the TT group.
Patient demographics and baseline disease characteris-
tics were generally well balanced between the groups,
with the exception of median disease duration, which
was higher in the PRN group than the TT group (8.5 vs
3.6 years, respectively) (Table 1). Over the first four ritux-
imab courses, a higher proportion of patients withdrew
from the PRN group (39% overall) than from the TT
group (19% overall). The most common reasons for
study withdrawal in the PRN group included insufficient
therapeutic response (12%) and treatment refusal (9%).
Withdrawals due to AEs were similar across groups: 5%
in the PRN group and 7% in the TT group (Fig. 1). In the
PRN group, 21% of patients withdrew during the first
course and 11% during the second course, compared
with 7 and 5% of patients in the TT group withdrawing
TABLE 1 Baseline characteristics
Characteristic
Rituximab
(2 1000mg)
PRN (n=257)
Rituximab
(2 1000mg)
TT (n=236)
Gender: female, % 78 82
Age, mean (S.D.) years 52 (11.3) 52 (12.5)
Median disease duration
(IQR), years
8.5 (3.914.9) 3.6 (1.59.9)
No. of previous DMARDs,
mean (S.D.)
2.0 (1.20) 1.2 (1.19)
Concomitant steroids, % 49 48
Concomitant NSAIDs, % 53 56
Swollen joint count (066),
mean (S.D.)
20 (10.8) 19 (10.2)
Tender joint count (068),
mean (S.D.)
32 (15.1) 30 (14.8)
CRP, mean (S.D.), mg/l 3.1 (3.44) 2.1 (2.44)
ESR, mean (S.D.), mm/h 42.7 (24.2) 45.1 (27.1)
HAQ-DI (03 range),
mean (S.D.)
1.7 (0.57) 1.6 (0.64)
DAS-28-ESR, mean (S.D.) 6.7 (0.95) 6.6 (1.03)
RF
+, % 81 73
Anti-CCP
+, % 78 80
Data are mean (±SD) or number (%) unless otherwise stated.
Anti-CCP, anti-cyclic citrullinated peptide; NSAIDs, non-
steroidal anti-inflammatory drugs; RF, rheumatoid factor.
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Retreatment strategies with rituximab in RAduring the first and second courses, respectively. The two
retreatment strategies resulted in significant differences in
the time between treatment courses. Within the PRN
group, the median time to retreatment for the first four
courses was 5263 weeks compared with  2526
weeks for the TT group (Fig. 2).
Clinical outcomes
Following the initial course of rituximab, both treatment re-
gimens demonstrated significant improvements in disease
activity and physical function, as evidenced by decreases
in both DAS-28-ESR and HAQ-DI compared with pre-
treatment baseline values (Fig. 3). Despite a slightly greater
initial decrease in disease activity from baseline to
Week 24 in the PRN group than in the TT group, consist-
ently greater mean changes in DAS-28-ESR were
observed in patients treated with the TT regimen from
24 weeks and over the longer term to Week 104
(Fig. 3a). Having adjusted for baseline characteristics,
these differences (ranging from 0.42 to 0.93 points) were
statistically significant from Week 40. A similar pattern of
improvement was observed for physical function through-
out the 2-year observation period, with consistently lower
mean HAQ-DI scores being achieved in the TT compared
with the PRN group (Fig. 3b). After adjusting for baseline
characteristics, these differences were statistically signifi-
cant from Week 56. Significantly more patients treated
using the TT regimen achieved a major clinical response
compared with patients in the PRN group (12.3 vs 5.1%;
P<0.05). Patients not responding to the initial treatment
course [as defined by a European League Against
Rheumatism (EULAR) non-response] demonstrated
some ability to respond to a subsequent treatment course.
Following the initial course of rituximab, 50/257 (19.5%)
and 66/236 (28%) PRN and TT patients, respectively,
were classed as EULAR non-responders at 24 weeks. A
FIG.1 .Patient disposition.
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and 65/66 (98.5%) PRN and TT non-responders, respect-
ively, with good or moderate EULAR responses being
achieved by 60.6 and 57.4% of patients in these groups,
respectively, 24 weeks later.
Control of disease within treatment courses
Measures of disease activity immediately before each
treatment course indicated that there was significantly
greater control of disease activity throughout each retreat-
ment course in patients treated according to the TT regi-
men. In these patients, the mean DAS-28-ESR immediately
before each course was consistently and statistically sig-
nificantly lower (4.64.9) than that observed pre-rituximab
(6.6) (Fig. 4a). In contrast, in patients treated according to
the PRN regimen, mean DAS-28-ESR before each course
(5.96.2) was similar to that pre-rituximab (6.7), indicating
loss of response during each course with this regimen
(Fig. 4a).
Greater control of disease activity in the TT group was
also demonstrated by a significantly lower proportion of
patients experiencing worsening of RA during each
course of rituximab (Fig. 4b). Over five courses, a disease
flare occurred in 734% of patients in the TT group com-
pared with 5484% of patients in the PRN group.
Safety outcomes
The number of patient-years of exposure was 977 (over a
maximum of 7.40 years) in the PRN group and 450 (over a
maximum of 2.77 years) in the TT group (Table 2). Despite
the higher frequency of administration of rituximab in the
TT group (median number of courses: four in the TT group
vs three in the PRN group), the safety profiles for
each regimen were generally comparable. Although the
overall rate of AEs was somewhat higher in the TT group
compared with the PRN group (364.3 vs 255.0 per
100 patient-years, respectively), the rates of SAEs, includ-
ing SIEs, were comparable between groups (Table 2).
The profile of AEs and SAEs was in line with that
typically observed with rituximab, and no new safety con-
cerns were identified. In both groups, the most frequently
reported AEs were infusion-related reactions, nasophar-
yngitis, upper respiratory tract infection, exacerbation of
RA and urinary tract infection, with bronchitis also
frequently reported only in the PRN group. The majority
of individual SAEs occurred in <1% of patients. Within the
TT group the only SAE to occur in >1% of patients
was OA (2%); whereas SAEs occurring in >1% of PRN
patients included exacerbation of RA (4%), OA (3%),
pneumonia (2%), lower respiratory tract infection (2%),
fall (2%) and myocardial infarction (2%).
Discussion
This retrospective analysis of MTX-IR patients receiving
multiple courses of rituximab suggests that a retreatment
regimen based on 24-week evaluations and a TT ap-
proach is associated with both improved efficacy and
tighter control of disease activity compared with PRN
treatment. Over a 2-year period, the TT regimen was
associated with significantly greater mean improvement
in disease activity and lower HAQ-DI scores than the
PRN regimen. From Week 40, the difference in disease
activity resulting from the two approaches was statistically
significant and considered to be clinically relevant.
Furthermore, significantly fewer patients treated using
the TT regimen experienced disease flares, with tighter
control of disease activity throughout each rituximab
treatment course.
FIG.2 .Median time to retreatment with rituximab 2 1000mg by course of rituximab.
y
P<0.001 (unadjusted for multiple
comparisons). Error bars represent interquartile range (Q1Q3).
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Retreatment strategies with rituximab in RAFIG.3 .Adjusted least square mean change from baseline in DAS-28-ESR (a) and adjusted least square mean HAQ-DI
over time (b). *P<0.05; **P<0.01;
y
P<0.001;
zP<0.0001 (all unadjusted for multiple comparisons). Error bars represent
95% CI.
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associated with an increased frequency of dosing, there
did not appear to be a significant impact on safety asso-
ciated with this regimen. Using all available data, the rates
of SAEs and SIEs seen with the TT strategy were compar-
able with those observed in PRN-treated patients.
Although the results of these described analyses are
clinically interesting, some important issues need to be
taken into consideration with regard to their interpretation.
This study was not a controlled, randomized assessment
with a pre-specified analysis plan; instead, data were
pooled from patients recruited into Phase II and III clinical
studies conducted over several years and in different
geographical locations. Therefore, this analysis has its
limitations. Patient withdrawals occurred more frequently
in the PRN population than in the TT population, the most
FIG.4 .Mean pre-course baseline DAS-28-ESR by course of rituximab (a) and patients with an increase in DAS-28-ESR
of 1.2 above the lowest DAS-28-ESR within the course (b).
y
P<0.001, t-test of change in DAS-28-ESR, within groups (a).
yP<0.001, Pearson’s chi-square between group difference (b).
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slightly lower incidence of EULAR non-response following
the first course of treatment in the PRN population).
It is of note that patients treated according to the PRN
regimen were primarily recruited during the early develop-
ment of rituximab, when data regarding the efficacy and
safety of rituximab in RA were limited. This could have
influenced both the population of patients recruited into
these studies as well as the frequency of retreatment with
rituximab according to the PRN regimen, with physicians
being more reluctant to administer repeat courses due to
the limited safety information on long-term B-cell deple-
tion. Additionally, there was some delay in the transition to
the long-term extension studies for patients following
the PRN regimen. Differences in the patient populations
recruited into the studies were low, although disease
duration was longer in the PRN population, possibly indi-
cating a selection bias for these patients. As the numbers
of patients withdrawing were small compared with the
overall retreatment populations, comparisons are there-
fore very limited. Propensity scores were used to adjust
for any differences between groups to provide estimates
of treatment effect. Another limitation of this analysis is
that the return of disease activity to pre-rituximab levels
in the PRN group is not unexpected as patients were re-
quired to have both tender and swollen joint counts 58t o
qualify for retreatment, which were the same criteria as
for inclusion. Therefore, these data should be interpreted
with caution.
It is important to acknowledge that somewhat subject-
ive investigator-assessed criteria were used for assess-
ments of response to initial treatments and for eligibility
for retreatment, and that these differed for the two treat-
ment regimens. In the analyses on rituximab treatment
reported here, a proportion of patients were shown to ex-
hibit improvement following additional rituximab courses
despite initially meeting criteria for non-response, an ob-
servation reported to varying degrees in previous studies
[15, 16]. In this study, patients classed as EULAR non-
responders at Week 24 did achieve decreases in DAS
upon additional courses of rituximab treatment, although
these decreases were more modest in comparison with
those of EULAR responders at the same time point.
Nonetheless, it is acknowledged that continued therapy
must be carefully considered in patients who show no
evidence of therapeutic benefit within 24 weeks.
It is encouraging that there were no apparent safety
concerns associated with the more frequent administra-
tion of rituximab in the TT group. Indeed, the rates of clin-
ically relevant events, such as SIEs, were numerically
lower in the TT population. However, such observations
may not be surprising given the potential association with
higher disease activity and greater risk of infection [22].
In contrast, the rates of overall AEs and overall infec-
tions appeared to be higher in the TT group. However,
it is of interest that the rates of these events in the TT
group are generally comparable with those previously re-
ported in the overall rituximab clinical trial programme.
Specifically, the rates of all AEs and all infections were
364.3 (95% CI 347.1, 382.4) and 111.9 (95% CI 102.5,
122.1) per 100 patient-years, respectively, in the TT popu-
lation and 359.6 (95% CI 354.4, 364.9) and 97.7 (95% CI
95.0, 100.5) per 100 patient-years within all clinical trials
[23]. Given that the rates of these events in the PRN group
were 255.0 (95% CI 245.2, 265.2) and 69.7 (95% CI 64.6,
75.1) per 100 patient-years, respectively, it could be sug-
gested that these events were uncharacteristically low in
the PRN population rather than unusually high in the TT
population.
The continued safety of the TT regimen, and the con-
sequences of continual peripheral B-cell depletion in-
duced by the TT approach over a longer observation
period, will require further investigation. It should also be
considered that, although both regimens were evaluated
for efficacy over a 2-year period in the current study, the
frequency of administration during this time was signifi-
cantly greater in the TT regimen, with a greater potential
for B-cell repopulation under the PRN regimen. However,
based on the current findings, and given the improved
efficacy, tighter control of disease and tolerable safety
profile, the benefit:risk ratio of the TT strategy with ritux-
imab appears favourable over the time period studied.
However, it must be accepted that as RA is a life-long dis-
ease, this benefit:risk ratio could change in the long term.
The findings from this evaluation are consistent with
data from the Belgian MabThera in RA (MIRA) registry,
which also illustrated the benefits of a retreatment to
target approach with rituximab [24]. In that study, retreat-
ment was administered from Week 24 in patients with
TABLE 2 Rates of AEs and SAEs
Outcome
Rituximab
(2 1000mg)
PRN (n=257)
Rituximab
(2 1000mg)
TT (n=236)
Mean years of exposure (minimum, maximum) 3.95 (0.23, 7.40) 1.97 (0.28, 2.77)
Patient-years 977 450
AEs/100 patient-years (95% CI) 255.0 (245.2, 265.2) 364.3 (347.1, 382.4)
SAEs/100 patient-years (95% CI) 16.0 (13.6, 18.7) 12.0 (9.2, 15.7)
Infections/100 patient-years (95% CI) 69.7 (64.6, 75.1) 111.9 (102.5, 122.1)
Serious infections/100 patient-years (95% CI) 3.4 (2.4, 4.8) 2.2 (1.2, 4.1)
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longer achieving the target of low disease activity rather
than remission, which was the target in the current study.
Retreatment with rituximab under these conditions also
resulted in lower DAS-28-ESR values at the start of the
second course compared with pre-rituximab values.
However, it was observed that at the point when patients
became eligible for retreatment (from Week 24 onwards),
the mean DAS-28-ESR was greater than at earlier time
points, indicating returning disease. Therefore, although
the study supports the concept of treating to target, the
tighter control of disease observed in the current study
was possibly achieved by targeting a lower disease level
(DAS-28-ESR <2.6 vs <3.2).
Although a target of DAS-28-ESR remission was used in
the present study, other disease activity measures, par-
ticularly those that are easier to apply by the rheumatolo-
gist, such as the Simplified Disease Activity Index and the
Clinical Disease Activity Index [25] or the Routine
Assessment of Patient Index Data 3 (RAPID3; [26]), may
be similarly effective. In contrast, as rituximab is a B-cell
depleting agent, it would be reasonable to hypothesize
that monitoring of B-cell levels may be instrumental in trig-
gering retreatment, and indeed by using a high-sensitivity
assay to identify poor B-cell depleters in non-responders
suitable patients for retreatment can be identified [27].
However, using conventional B-cell analysis, no correl-
ation between peripheral B cells and clinical response
has been found [28], indicating that monitoring peripheral
B-cell levels by such methods may not be of use as a
determinant for retreatment with rituximab.
In summary, and while acknowledging the limitations of
these evaluations, it can be concluded that retreatment
with rituximab, based on 24-week evaluations and treat-
ment to a target of DAS-28-ESR remission, leads to
improved efficacy and tighter control of disease activity
compared with a PRN regimen. Rituximab TT may be
the preferable regimen for the treatment of patients
with RA.
Rheumatology key messages
. TT of DAS-28-ESR remission with rituximab may
provide improved efficacy vs PRN treatment.
. PRN treatment led to recurrence of disease activity
to pre-treatment baseline levels between treatment
courses.
. TT of DAS-28-ESR remission may be the preferred
rituximab application in RA.
Acknowledgements
Support for third-party writing assistance for this manu-
script was provided by F. Hoffmann-La Roche, Genentech
Inc. and Biogen Idec.
Funding: This work was funded by F. Hoffmann-La Roche,
Genentech Inc. and Biogen Idec.
Disclosure statement: N.B.G. has received research
grants and consulting fees from Genentech. A.R.-R. has
received honoraria and is a member of a speakers’ bureau
for Roche. P.E. has undertaken clinical trials and provided
expert advice for Roche, Abbott, Pfizer, MSD and BMS.
U.M.-L. is a speaker for and advisor to Roche. H.T. is an
employee of Roche. M.R. is an employee of and owns
stock in Roche. P.J.M. receives consulting fees, speaker
honoraria and research grants from Abbott, Amgen,
Biogen Idec, BMS, Centocor, Crescendo, Genentech,
Pfizer, Roche and UCB. J.R.C. has received honoraria,
grant/research support and is a consultant for Roche/
Genentech. S.W. is an employee of Roche.
Supplementary data
Supplementary data are available at Rheumatology
Online.
References
1 Schoels M, Knevel R, Aletaha D et al. Evidence for treating
rheumatoid arthritis to target: results of a systematic
literature search. Ann Rheum Dis 2010;69:63843.
2 Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW. Tight
control in the treatment of rheumatoid arthritis: efficacy
and feasibility. Ann Rheum Dis 2007;66(Suppl. 3):iii5660.
3 Grigor C, Capell H, Stirling A et al. Effect of a treatment
strategy of tight control for rheumatoid arthritis (the
TICORA study): a single-blind randomised controlled trial.
Lancet 2004;364:2639.
4 Tanaka E, Mannalithara A, Inoue E et al. Efficient
management of rheumatoid arthritis significantly reduces
long-term functional disability. Ann Rheum Dis 2008;67:
11538.
5 Goekoop-Ruiterman YP, Vries-Bouwstra JK, Allaart CF
et al. Clinical and radiographic outcomes of four different
treatment strategies in patients with early rheumatoid
arthritis (the BeSt study): a randomized, controlled trial.
Arthritis Rheum 2005;52:338190.
6 Smolen JS, Aletaha D, Bijlsma JW et al. Treating
rheumatoid arthritis to target: recommendations of an
international task force. Ann Rheum Dis 2010;69:6317.
7 Allaart CF, Goekoop-Ruiterman YP, de Vries-
Bouwstra JK, Breedveld FC, Dijkmans BA. Aiming at
low disease activity in rheumatoid arthritis with initial
combination therapy or initial monotherapy strategies:
the BeSt study. Clin Exp Rheumatol 2006;24(6 Suppl. 43):
S-7782.
8 Saag KG, Teng GG, Patkar NM et al. American College of
Rheumatology 2008 recommendations for the use of
nonbiologic and biologic disease-modifying antirheumatic
drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:
76284.
9 Combe B, Landewe R, Lukas C et al. EULAR recommen-
dations for the management of early arthritis: report of a
task force of the European Standing Committee for
International Clinical Studies Including Therapeutics
(ESCISIT). Ann Rheum Dis 2007;66:3445.
10 Schoels M, Aletaha D, Smolen JS et al. Follow-up
standards and treatment targets in Rheumatoid Arthritis
www.rheumatology.oxfordjournals.org 2231
Retreatment strategies with rituximab in RA(RA): Results of a questionnaire at the EULAR 2008.
Ann Rheum Dis 2010;69:5758.
11 Keystone E, Emery P, Peterfy CG et al. Rituximab inhibits
structural joint damage in patients with rheumatoid
arthritis with an inadequate response to tumour
necrosis factor inhibitor therapies. Ann Rheum Dis 2009;
68:21621.
12 Cohen SB, Emery P, Greenwald MW et al. Rituximab for
rheumatoid arthritis refractory to anti-tumor necrosis
factor therapy: results of a multicenter, randomized,
double-blind, placebo-controlled, phase III trial evaluating
primary efficacy and safety at twenty-four weeks. Arthritis
Rheum 2006;54:2793806.
13 Emery P, Deodhar A, Rigby WF et al. Efficacy and
safety of different doses and retreatment of rituximab:
a randomised, placebo-controlled trial in patients
who are biological naive with active rheumatoid
arthritis and an inadequate response to methotrexate
(Study Evaluating Rituximab’s Efficacy in MTX
iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010;
69:162935.
14 Edwards JC, Szczepan ˜ski L, Szechin ˜ski J et al. Efficacy
of B-cell-targeted therapy with rituximab in patients
with rheumatoid arthritis. N Engl J Med 2004;350:
257281.
15 Mease PJ, Cohen S, Gaylis NB et al. Efficacy and safety
of retreatment in patients with rheumatoid arthritis with
previous inadequate response to tumor necrosis factor
inhibitors: results from the SUNRISE Trial. J Rheumatol
2010;37:91727.
16 Rubbert-Roth A, Tak PP, Zerbini C et al. Efficacy and
safety of various repeat treatment dosing regimens of
rituximab in patients with active rheumatoid arthritis:
results of a Phase III randomized study (MIRROR).
Rheumatology 2010;49:168393.
17 Emery P, Fleischmann R, Filipowicz-Sosnowska A et al.
The efficacy and safety of rituximab in patients with active
rheumatoid arthritis despite methotrexate treatment:
Results of a phase IIB randomized, double-blind,
placebo-controlled, dose-ranging trial. Arthritis Rheum
2006;54:1390400.
18 Keystone E, Fleischmann R, Emery P et al. Safety and
efficacy of additional courses of rituximab in patients
with active rheumatoid arthritis: an open-label extension
analysis. Arthritis Rheum 2007;56:3896908.
19 Arnett FC, Edworthy SM, Bloch DA et al. The American
Rheumatism Association 1987 revised criteria for the
classification of rheumatoid arthritis. Arthritis Rheum 1988;
31:31524.
20 Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA,
van de Putte LB, van Riel PL. Modified disease activity
scores that include twenty-eight-joint counts.
Development and validation in a prospective longitudinal
study of patients with rheumatoid arthritis. Arthritis Rheum
1995;38:448.
21 Fries JF, Spitz P, Kraines RG, Holman HR. Measurement
of patient outcome in arthritis. Arthritis Rheum 1980;23:
13745.
22 Furst DE, Kremer J, Strand V, Reed G, Greenberg J.
The rate of infection adverse events (AEs) is increased
as disease activity increases in rheumatoid arthritis (RA).
Arthritis Rheum 2007;56(Suppl. 9):Abstract 958.
23 van Vollenhoven RF, Emery P, Bingham CO III et al.
Longterm safety of patients receiving rituximab in
rheumatoid arthritis clinical trials. J Rheumatol 2010;37:
55867.
24 Vander Cruyssen B, Westhovens R, Durez P, de Keyser F;
MIRA Study Group. The Belgian MIRA (MabThera in
Rheumatoid Arthritis) Registry: Clues for the optimization
of rituximab treatment strategies. Arthritis Rheum 2009;
60(Suppl. 10):Abstract 993.
25 Aletaha D, Landewe R, Karonitsch T et al. Reporting
disease activity in clinical trials of patients with rheumatoid
arthritis: EULAR/ACR collaborative recommendations.
Ann Rheum Dis 2008;67:13604.
26 Pincus T, Swearingen CJ, Bergman MJ et al. RAPID3
(Routine Assessment of Patient Index Data) on an MDHAQ
(Multidimensional Health Assessment Questionnaire):
agreement with DAS28 (Disease Activity Score) and CDAI
(Clinical Disease Activity Index) activity categories, scored
in five versus more than ninety seconds. Arthritis Care Res
2010;62:1819.
27 Vital EM, Dass S, Rawstron AC et al. Management of
non-response to rituximab in rheumatoid arthritis:
predictors and outcome of retreatment. Arthritis Rheum
2010;62:12739.
28 Dass S, Rawstron AC, Vital EM, Henshaw K,
McGonagle D, Emery P. Highly sensitive B cell analysis
predicts response to rituximab therapy in rheumatoid
arthritis. Arthritis Rheum 2008;58:29939.
2232 www.rheumatology.oxfordjournals.org
Paul Emery et al.